Killer instincts: natural killer cells as multifactorial cancer immunotherapy
S Nersesian, EB Carter, SN Lee, LP Westhaver… - Frontiers in …, 2023 - frontiersin.org
Natural killer (NK) cells integrate heterogeneous signals for activation and inhibition using
germline-encoded receptors. These receptors are stochastically co-expressed, and their …
germline-encoded receptors. These receptors are stochastically co-expressed, and their …
HLA-C: Evolution, epigenetics, and pathological implications in the major histocompatibility complex
HLA-C, a gene located within the major histocompatibility complex, has emerged as a
prominent target in biomedical research due to its involvement in various diseases …
prominent target in biomedical research due to its involvement in various diseases …
Genome-wide association study in acute tubulointerstitial nephritis
Background Acute tubulointerstitial nephritis (ATIN) is a rare immune-related disease,
accounting for approximately 10% of patients with unexplained AKI. Previous elucidation of …
accounting for approximately 10% of patients with unexplained AKI. Previous elucidation of …
CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017–2023)
J Shi, X Liu, Y Jiang, M Gao, J Yu, Y Zhang… - Frontiers in …, 2024 - frontiersin.org
Background Chimeric antigen receptor T-cell (CAR-T) therapy, a rapidly emerging treatment
for cancer that has gained momentum since its approval by the FDA in 2017, involves the …
for cancer that has gained momentum since its approval by the FDA in 2017, involves the …
The impact of killer cell immunoglobulin-like receptor (KIR) genes and human leukocyte antigen (HLA) class I ligands on predisposition or protection against prostate …
Natural killer (NK) cell development largely depends on killer cell immunoglobulin-like
receptors (KIRs) and human leukocyte antigen (HLA) class I ligands. In the current study, we …
receptors (KIRs) and human leukocyte antigen (HLA) class I ligands. In the current study, we …
Using immunogenetics to inform immunotherapy of lymphoid malignancies
L Vago, AJM Ferreri - The Lancet Haematology, 2022 - thelancet.com
Immunotherapy is changing perspectives in haematological and solid tumours.
Advancements in this field are being made quickly, with a large body of related literature …
Advancements in this field are being made quickly, with a large body of related literature …